Health Care & Life Sciences » Biotechnology | Aquinox Pharmaceuticals Inc.

Aquinox Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
56,946.50
39,097.30
74,482.00
103,059.00
108,085.00
76,928
Total Accounts Receivable
27.90
65.40
32.00
-
-
-
Other Current Assets
64.00
139.00
282.00
426.00
740.00
237
Total Current Assets
57,038.50
39,301.80
74,796.00
103,485.00
108,825.00
77,165
Net Property, Plant & Equipment
75.50
104.70
89.00
849.00
905.00
400
Total Investments and Advances
-
2,003.10
38,458.00
50,046.00
-
-
Intangible Assets
62.50
-
-
-
-
-
Other Assets
1,592.20
13.40
-
-
599.00
53
Total Assets
58,768.60
41,422.90
113,343.00
154,380.00
110,329.00
77,618
ST Debt & Current Portion LT Debt
250.00
-
-
-
-
Accounts Payable
599.80
734.20
-
-
-
Other Current Liabilities
1,770.30
4,469.10
4,792.00
9,519.00
10,956.00
Total Current Liabilities
2,620.10
5,203.30
4,792.00
9,519.00
10,956.00
Long-Term Debt
2,036.50
72.30
131.00
47.00
33.00
Provision for Risks & Charges
1,797.40
-
-
-
-
Other Liabilities
1,030.10
-
-
150.00
453.00
Total Liabilities
7,484.10
5,275.60
4,923.00
9,716.00
11,442.00
Common Equity (Total)
51,284.60
36,147.30
108,420.00
144,664.00
98,887.00
Total Shareholders' Equity
51,284.60
36,147.30
108,420.00
144,664.00
98,887.00
Total Equity
51,284.60
36,147.30
108,420.00
144,664.00
98,887.00
Liabilities & Shareholders' Equity
58,768.60
41,422.90
113,343.00
154,380.00
110,329.00

About Aquinox Pharmaceuticals

View Profile
Address
887 Great Northern Way
Vancouver British Columbia V5T 4T5
Canada
Employees -
Website http://www.aqxpharma.com
Updated 07/08/2019
Aquinox Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway.